Sunpointe LLC Acquires Shares of 9,702 Kenvue Inc. (NYSE:KVUE)

Sunpointe LLC purchased a new position in shares of Kenvue Inc. (NYSE:KVUE) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 9,702 shares of the company’s stock, valued at approximately $207,000.

A number of other institutional investors and hedge funds have also made changes to their positions in KVUE. AMF Tjanstepension AB increased its stake in shares of Kenvue by 187.3% during the third quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock worth $2,787,000 after acquiring an additional 78,540 shares during the period. Sequoia Financial Advisors LLC increased its stake in shares of Kenvue by 6.2% during the third quarter. Sequoia Financial Advisors LLC now owns 24,690 shares of the company’s stock worth $571,000 after acquiring an additional 1,449 shares during the period. Signaturefd LLC increased its stake in shares of Kenvue by 394.0% during the third quarter. Signaturefd LLC now owns 4,061 shares of the company’s stock worth $94,000 after acquiring an additional 3,239 shares during the period. Commerzbank Aktiengesellschaft FI acquired a new position in shares of Kenvue during the third quarter worth about $292,000. Finally, International Assets Investment Management LLC increased its stake in shares of Kenvue by 1,529.5% during the third quarter. International Assets Investment Management LLC now owns 106,341 shares of the company’s stock worth $2,460,000 after acquiring an additional 99,815 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 0.5 %

Shares of NYSE KVUE opened at $22.38 on Friday. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The company has a market capitalization of $42.90 billion, a PE ratio of 42.22, a price-to-earnings-growth ratio of 2.57 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The firm’s 50-day moving average is $21.29 and its two-hundred day moving average is $22.14.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.66%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio is presently 154.72%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on KVUE shares. Barclays dropped their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Canaccord Genuity Group decreased their price objective on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Citigroup decreased their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a report on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.